What is CathWorks?
CathWorks is a pioneering medical technology firm dedicated to transforming the diagnosis and treatment of cardiovascular disease through advanced computational science. The company's core platform enhances coronary angiography by providing physicians with objective, real-time physiological assessments of coronary artery disease. By leveraging sophisticated software to evaluate coronary blood flow, CathWorks enables clinicians to make informed, precise treatment decisions without the necessity of invasive pressure wires. This innovation significantly optimizes clinical workflows, reducing the reliance on costly and complex procedures while improving patient outcomes. Positioned at the intersection of cardiology and digital health, CathWorks is redefining the standard of care in cardiac catheterization labs globally.
How much funding has CathWorks raised?
CathWorks has raised a total of $75.8M across 3 funding rounds:
Series B
$15.8M
Series C
$30M
Series D
$30M
Series B (2017): $15.8M with participation from Corundum Open Innovation, TriVentures, Pontifax, Quark Ventures, Planven Investments, and BioStar Capital
Series C (2019): $30M led by Deerfield
Series D (2021): $30M, investors not publicly disclosed
Key Investors in CathWorks
Corundum Open Innovation
An Israel-Japan venture capital firm that focuses on high-tech sectors including life sciences and artificial intelligence, providing unique market insights and business development support.
TriVentures
A global venture capital fund specializing in early-stage healthcare breakthroughs, with a specific focus on bio-convergence and data-driven medical technologies.
Pontifax
A life sciences-focused venture capital firm that scouts disruptive innovations and provides hands-on guidance to clinical-stage companies to maximize their success in capital markets.
What's next for CathWorks?
With the recent influx of capital, CathWorks is well-positioned to accelerate its commercialization efforts and deepen its penetration into global cardiac care markets. The strategic focus will likely shift toward scaling its software-as-a-service (SaaS) delivery model and expanding its clinical evidence base to support broader adoption among interventional cardiologists. As the company matures, it is expected to leverage its robust data capabilities to further integrate into routine hospital workflows, potentially exploring new diagnostic applications within the cardiovascular space. The firm's commitment to non-invasive, high-precision diagnostics remains the cornerstone of its long-term growth strategy, ensuring it remains a key player in the evolving landscape of medical device innovation.
See full CathWorks company page
